AUGTYRO

This brand name is authorized in United States. It is also authorized in Lithuania.

Active ingredients

The drug AUGTYRO contains one active pharmaceutical ingredient (API):

1	Repotrectinib UNII 08O3FQ4UNP - REPOTRECTINIB
	Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1, the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, TRKC, and anaplastic lymphoma kinase (ALK). Repotrectinib has demonstrated in vitro and in vivo inhibition of cell lines expressing the targeted fusion oncogenes ROS1, TRKA, TRKB, TRKC, and corresponding mutations (ROS1G2032R, ROS1D2033N, TRKAG595R, TRKBG639R, TRKCG623R).
	Read more about Repotrectinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AUGTYRO Capsule, hard	MPI, EU: SmPC	European Medicines Agency (EU)
AUGTYRO Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX28		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX28

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1102333, 1102334, 1102335, 1102336
US	FDA, National Drug Code	0003-4040, 0003-4160